Business
Zura Bio Continues to Strengthen Leadership with Appointment of Robert Lisicki as President and Kiran Nistala as CMO
Accomplished biopharmaceutical executives bring invaluable expertise and experience to Zura Bio’s Clinical Development programs Executive Leadership hires
About this update from Zura Bio Limited
[{"type":"text","content":"\n\nAccomplished biopharmaceutical executives bring invaluable expertise and experience to Zura Bio’s Clinical Development programs\n\n\n\nExecutive Leadership hires position Zura Bio for Phase 2 clinical trial readiness across multiple indications in 2024\n\n\n\n HENDERSON, Nev.--(BUSINESS WIRE)--\nZura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, today announced the appointments of Robert Lisicki as President and Chief Operating Officer, and Kiran Nistala, MBBS, PhD, as Executive Vice President Development and Chief Medical Officer, to the Executive Leadership Team. Mr. Lisicki will be responsible for developing and driving the business plan and strategic initiatives as Zura Bio builds a leading immunology company. Dr. Nistala will be responsible for the development strategy of prioritized pipeline products. Mr. Lisicki and Dr. Nistala have successfully worked on or led in the development of multiple drugs within the auto-immune therapeutic area. These executives position Zura Bio to deliver on the promise of their innovative medicines for patients in need of better clinical outcomes.\n\nThis press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240108851979/en/Robert Lisicki (Photo: Business Wire)\n“I am very pleased to welcome Rob and Kiran to Zura Bio as members of the Executive Team. Both are accomplished global biopharma leaders, with multiple drug approvals to their credit,” said Dr. Someit Sidhu, Founder, CEO and Director of Zura Bio. “We are at a crucial inflection point for the organization as we initiate multiple Phase 2 clinical trials in 2024. Rob and Kiran have dedicated much of their careers to delivering results across multiple complex and diverse development programs while building and maintaining high functioning teams. We welcome their expertise and track record of success as we establish Zura Bio as a preeminent global immunology company.”\n\n\nMr. Lisicki is an experienced executive leader with a career spanning nearly 30 years in the biopharmaceutical industry. Mr. Lisicki served as the Chief Commercial Officer at Arena Pharmaceuticals; a prominent biopharmaceutical company acquired by Pfizer for $6.7 billion in 2022. “I worked with Ro...